Search by Drug Name or NDC
NDC 70710-1901-03 Sitagliptin 100 mg/1 Details
Sitagliptin 100 mg/1
Sitagliptin is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Zydus Pharmaceuticals (USA) Inc.. The primary component is SITAGLIPTIN.
MedlinePlus Drug Summary
Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Sitagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amounts of certain natural substances that lower blood sugar when it is high. Sitagliptin is not used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Taking medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes.
Related Packages: 70710-1901-03Last Updated: 05/12/2024
MedLinePlus Full Drug Details: Sitagliptin
Product Information
NDC | 70710-1901 |
---|---|
Product ID | 70710-1901_e6912c3b-b985-4107-8093-82654bc1a3bb |
Associated GPIs | |
GCN Sequence Number | n/a |
GCN Sequence Number Description | n/a |
HIC3 | n/a |
HIC3 Description | n/a |
GCN | n/a |
HICL Sequence Number | n/a |
HICL Sequence Number Description | n/a |
Brand/Generic | n/a |
Proprietary Name | Sitagliptin |
Proprietary Name Suffix | n/a |
Non-Proprietary Name | Sitagliptin |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | TABLET |
Route | ORAL |
Active Ingredient Strength | 100 |
Active Ingredient Units | mg/1 |
Substance Name | SITAGLIPTIN |
Labeler Name | Zydus Pharmaceuticals (USA) Inc. |
Pharmaceutical Class | Dipeptidyl Peptidase 4 Inhibitor [EPC], Dipeptidyl Peptidase 4 Inhibitors [MoA] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA211566 |
Listing Certified Through | 2024-12-31 |
Package
NDC 70710-1901-03 (70710190103)
NDC Package Code | 70710-1901-3 |
---|---|
Billing NDC | 70710190103 |
Package | 30 TABLET in 1 BOTTLE (70710-1901-3) |
Marketing Start Date | 2023-11-30 |
NDC Exclude Flag | N |
Pricing Information | N/A |